

Methoxy polyethylene glycol-epoetin beta (Mircera[®]) Protocol

Methoxy polyethylene glycol-epoetin beta (Mircera[®]) ICD 10 code D63.1
Anemia in chronic kidney disease

Purpose: To provide optimal management of ESRD related anemia in dialysis patients

Hemoglobin Target Goal: 10.0-11.0 g/dL

Methoxy polyethylene glycol-epoetin beta Dosing:

Doses are based on estimated dry weight and rounded to the following steps:

Step	Dose
1	30 mcg every four weeks
2	50 mcg every four weeks
3	30 mcg every two weeks
4	50 mcg every two weeks
5	60 mcg every two weeks (30 mcg + 30 mcg)
6	75 mcg every two weeks
7	100 mcg every two weeks
8	150 mcg every two weeks
9	200 mcg every two weeks

Table 1

1. Methoxy polyethylene glycol-epoetin (Mircera[®]) will be increased and decreased in 1-step or 2-step increments, based on scale above.
2. Mircera[®] will be administered IV to in-center hemodialysis patients, and SQ to home dialysis patients.
3. Mircera[®] ceiling is 200 mcg every two weeks (or 3.0 mcg/kg every 2 weeks, whichever is lower). Orders above 200mcg every two weeks require facility medical director or CMO approval.
4. For in-center hemodialysis patients, if pre-dialysis systolic blood pressure is >190 mm Hg, do not administer Mircera[®]. Notify nephrologist and administer Mircera[®] dose at next hemodialysis session if systolic blood pressure is <190 mm Hg at that time.

Initiating Mircera[®] for new patients or ESA naïve patients

For new patients

Patient Name _____ NKC# _____

Patient Name _____ NK# _____